Country: Japan
Language: English
Source: すりの適正使用協議会 RAD-AR Council, Japan
Ranibizumab(genetical recombination)[ranibizumab biosimilar 1]
SENJU PHARMACEUTICAL CO.,LTD.
Ranibizumab(genetical recombination)[ranibizumab biosimilar 1]
injection
Drug Information Sheet("Kusuri-no-Shiori") Injection Published: 03/2023 The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment. BRAND NAME: RANIBIZUMAB BS INTRAVITREAL INJECTION KIT 10MG/ML "SENJU" [DIABETIC MACULAR EDEMA] ACTIVE INGREDIENT: Ranibizumab(genetical recombination)[ranibizumab biosimilar 1] DOSAGE FORM: injection IMPRINT OR PRINT ON WRAPPING: EFFECTS OF THIS MEDICINE This medicine inhibits vascular endothelial growth factor (VEGF) which is involved in leakage of blood component from the retinal vessels and reduces the amount of leakage to improve macular edema. As a result, it improves failing vision. It is usually used to treat diabetic macular edema. THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS MEDICINE.BE SURE TO TELL YOUR DOCTOR AND PHARMACIST. ・If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines or foods. If you have: ocular/periocular infections or suspected of them, intraocular inflammation, a history of stroke or transient ischemic attack. ・If you are pregnant or breastfeeding. ・If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.) DOSING SCHEDULE (HOW TO TAKE THIS MEDICINE) ・ Your dosing schedule prescribed by your doctor is(( to be written by a healthcare professional )) ・In general, administer by intraocular (intravitreal) injection once. After initial dose, your symptoms and response to the treatment should be assessed monthly, and additional treatment may be given as needed. T Read the complete document